+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha 1 Antitrypsin Deficiency Treatment - Global Market Trajectory & Analytics

  • ID: 5309866
  • Report
  • April 2021
  • Region: Global
  • 235 pages
  • Global Industry Analysts, Inc
Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach $2.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Augmentation Therapy, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bronchodilator segment is readjusted to a revised 9.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $463.6 Million, While China is Forecast to Grow at 8.3% CAGR

The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$463.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$493.1 Million by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Corticosteroids Segment to Record 7.7% CAGR

In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$189.6 Million in the year 2020 will reach a projected size of US$319.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$328.4 Million by the year 2027.

Select Competitors (Total 46 Featured):
  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring
  • Curaxys
  • GlaxoSmithKline PLC
  • Grifols International SA
  • Kamada Ltd.
  • Pfizer, Inc.
  • ProBioGen AG
  • ProMetic Life Sciences, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS
  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • REST OF EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll